Pulmonx (NASDAQ:LUNG) Insider Sells $11,056.76 in Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Geoffrey Beran Rose sold 7,732 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $1.43, for a total transaction of $11,056.76. Following the completion of the sale, the insider directly owned 365,734 shares of the company’s stock, valued at approximately $522,999.62. The trade was a 2.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Pulmonx Stock Performance

Shares of LUNG traded down $0.09 during mid-day trading on Wednesday, hitting $1.44. 579,968 shares of the company’s stock were exchanged, compared to its average volume of 360,844. The stock’s 50-day simple moving average is $1.79 and its 200-day simple moving average is $1.79. Pulmonx Corporation has a 52 week low of $1.31 and a 52 week high of $8.71. The company has a quick ratio of 4.15, a current ratio of 4.86 and a debt-to-equity ratio of 0.62.

Analysts Set New Price Targets

LUNG has been the subject of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Pulmonx in a report on Thursday, January 22nd. D. Boral Capital reissued a “buy” rating and set a $14.00 price objective on shares of Pulmonx in a report on Friday, February 20th. Finally, Wall Street Zen raised Pulmonx from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Five investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pulmonx currently has a consensus rating of “Hold” and an average target price of $6.81.

Hedge Funds Weigh In On Pulmonx

A number of hedge funds have recently made changes to their positions in the stock. Cerity Partners LLC bought a new position in Pulmonx during the 4th quarter worth approximately $27,000. FNY Investment Advisers LLC acquired a new stake in shares of Pulmonx during the third quarter worth $29,000. Opal Capital LLC bought a new position in Pulmonx during the fourth quarter worth $29,000. Regatta Capital Group LLC acquired a new position in Pulmonx in the fourth quarter valued at $30,000. Finally, Jain Global LLC bought a new stake in shares of Pulmonx during the 3rd quarter valued at about $30,000. 91.04% of the stock is currently owned by institutional investors.

Key Stories Impacting Pulmonx

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Pulmonx closed a five‑year credit facility of up to $60 million with Perceptive Advisors that includes a $40M term loan (with an option for an additional $20M tied to revenue milestones). Management says the financing extends debt maturity to 2031 and strengthens the balance sheet to support commercial and clinical priorities. Article Title
• Positive Sentiment: Q4 results showed improvement vs. a year ago: narrower GAAP loss ($0.25/sh) and adjusted EBITDA loss improved; full‑year 2025 revenue rose to $90.5M (up 8% YoY) and gross margin expanded to ~78% in Q4 — evidence of operating leverage and cost reductions. Article Title
• Neutral Sentiment: Management issued 2026 revenue guidance of $90M–$92M and expects ~75% gross margin with operating expenses $113M–$115M — guidance gives visibility but comes in below some analyst estimates, leaving mixed signals on near‑term topline momentum. Article Title
• Negative Sentiment: Several insiders sold stock on March 2 (including CEO Glendon E. French III, General Counsel David A. Lehman, CCO Geoffrey Beran Rose and Senior staff), representing multiple percent reductions in their holdings — heavy insider selling can pressure sentiment and amplify downside. SEC filings: CEO sale CEO Form 4, Lehman GC Form 4, Beran Rose CCO Form 4, Srikanth Radhakrishnan Form 4
• Negative Sentiment: Q4 U.S. revenue declined (~11% YoY) and total Q4 revenue was down ~5% YoY, signaling softer commercial momentum in Pulmonx’s largest market — the company emphasized a transition plan to reaccelerate U.S. sales, but near‑term growth risk weighed on the stock. Article Title

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.